134 related articles for article (PubMed ID: 38314144)
21. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations.
Haupt R; Fears TR; Heise A; Gadner H; Loiacono G; De Terlizzi M; Tucker MA
Int J Cancer; 1997 Mar; 71(1):9-13. PubMed ID: 9096658
[TBL] [Abstract][Full Text] [Related]
22. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
[TBL] [Abstract][Full Text] [Related]
23. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
Ritke MK; Rusnak JM; Lazo JS; Allan WP; Dive C; Heer S; Yalowich JC
Mol Pharmacol; 1994 Oct; 46(4):605-11. PubMed ID: 7969039
[TBL] [Abstract][Full Text] [Related]
24. [Synergetic cytotoxicity of cisplatin and etoposide to leukemia cell line K562 and its mechanism].
Ma WD; Yin MY; Jiang CW; Xu SR; Zhai LD; Zheng LF; Wang YL; Yan YL
Ai Zheng; 2005 Aug; 24(8):958-64. PubMed ID: 16086873
[TBL] [Abstract][Full Text] [Related]
25. Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.
Sinha BK; Kumar A; Bhattacharjee S; Espey MG; Mason RP
J Pharmacol Exp Ther; 2013 Dec; 347(3):607-14. PubMed ID: 24049059
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide.
Lotfi K; Månsson E; Chandra J; Wang Y; Xu D; Knaust E; Spasokoukotskaja T; Liliemark E; Eriksson S; Albertioni F
Br J Haematol; 2001 May; 113(2):339-46. PubMed ID: 11380397
[TBL] [Abstract][Full Text] [Related]
27. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
Van Echo DA; Wiernik PH; Aisner J
Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027
[TBL] [Abstract][Full Text] [Related]
28. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
[TBL] [Abstract][Full Text] [Related]
29. The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells.
Boulares AH; Zoltoski AJ; Sherif ZA; Yakovlev AG; Smulson ME
Cancer Res; 2002 Aug; 62(15):4439-44. PubMed ID: 12154052
[TBL] [Abstract][Full Text] [Related]
30. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Vey N; Kantarjian H; Beran M; O'Brien S; Cortes J; Koller C; Estey E
Invest New Drugs; 1999; 17(1):89-95. PubMed ID: 10555127
[TBL] [Abstract][Full Text] [Related]
31. Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway.
Nam C; Doi K; Nakayama H
Histol Histopathol; 2010 Apr; 25(4):485-93. PubMed ID: 20183801
[TBL] [Abstract][Full Text] [Related]
32. Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia.
Shigematsu A; Tanaka J; Suzuki R; Atsuta Y; Kawase T; Ito YM; Yamashita T; Fukuda T; Kumano K; Iwato K; Yoshiba F; Kanamori H; Kobayashi N; Fukuhara T; Morishima Y; Imamura M
Int J Hematol; 2011 Nov; 94(5):463-71. PubMed ID: 22042561
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus oncoprotein E4orf6 triggers Cullin5 neddylation to activate the CLR5 E3 ligase for p53 degradation.
Guo H; Shen S; Li Y; Bi R; Zhang N; Zheng W; Deng Y; Yang Y; Yu XF; Wang C; Wei W
Biochem Biophys Res Commun; 2019 Sep; 516(4):1242-1247. PubMed ID: 31301771
[TBL] [Abstract][Full Text] [Related]
34. Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.
Dong Q; Zhou C; Ren H; Zhang Z; Cheng F; Xiong Z; Chen C; Yang J; Gao J; Zhang Y; Xu L; Fang J; Cao Y; Wei H; Wu Z
Cell Commun Signal; 2020 Oct; 18(1):167. PubMed ID: 33097055
[TBL] [Abstract][Full Text] [Related]
35. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
36. Characterization of an etoposide-resistant human ovarian cancer cell line.
Kubota N; Nishio K; Takeda Y; Ohmori T; Funayama Y; Ogasawara H; Ohira T; Kunikane H; Terashima Y; Saijo N
Cancer Chemother Pharmacol; 1994; 34(3):183-90. PubMed ID: 7911742
[TBL] [Abstract][Full Text] [Related]
37. Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide.
Biasoli D; Kahn SA; Cornélio TA; Furtado M; Campanati L; Chneiweiss H; Moura-Neto V; Borges HL
Cell Death Dis; 2013 Aug; 4(8):e767. PubMed ID: 23949216
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.
Czyz A; Labopin M; Giebel S; Socié G; Apperley J; Volin L; Reményi P; Yakoub-Agha I; Orchard K; Michallet M; Stuhler G; Chaganti S; Murray M; Aljurf M; Bloor A; Passweg J; Finke J; Mohty M; Nagler A
Am J Hematol; 2018 Jun; 93(6):778-785. PubMed ID: 29574915
[TBL] [Abstract][Full Text] [Related]
39. Comparison of DR5 and Fas expression levels relative to the chemosensitivity of acute lymphoblastic leukemia cell lines.
Lam V; Findley HW; Reed JC; Freedman MH; Goldenberg GJ
Leuk Res; 2002 May; 26(5):503-13. PubMed ID: 11916527
[TBL] [Abstract][Full Text] [Related]
40. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
